Physician profile
David G Sidebottom
NPI 1174580898
$32,171.60
in general payments reported to CMS, 2019-2025
25 companies · $6,752 in 2025
The $6,752 reported for 2025 was more than what 91% of Infectious Disease providers received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11K · 2020: $1,920 · 2021: $2,265 · 2022: $1,629 · 2023: $2,654 · 2024: $5,688 · 2025: $6,752.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $8,380 · Food and Beverage: $6,428 · Education: $160 · Travel and Lodging: $126.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $8,380.00 |
| Food and Beverage | $6,427.68 |
| Education | $159.80 |
| Travel and Lodging | $125.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $10,640.51 | 2019-2025 | Dalvance, Teflaro, Avycaz |
| Insmed, INC. | $9,126.15 | 2019-2025 | Arikayce, Brinsupri |
| Gilead Sciences, INC. | $5,186.14 | 2019-2025 | Descovy, Epclusa, Yeztugo |
| Viiv Healthcare Company | $2,076.75 | 2019-2025 | Dovato, Cabenuva, Apretude |
| Merck Sharp & Dohme LLC | $957.86 | 2019-2024 | |
| Cepheid | $920.00 | 2020-2023 | |
| Janssen Biotech, INC. | $850.39 | 2019-2023 | Symtuza |
| Paratek Pharmaceuticals, INC. | $717.88 | 2021-2025 | Nuzyra |
| Allergan, INC. | $296.89 | 2019-2020 | |
| Pfizer INC. | $233.86 | 2021-2025 | |
| Janssen Products, LP | $228.98 | 2019-2021 | |
| Astellas Pharma US INC | $194.94 | 2019-2025 | Cresemba |
| Becton, Dickinson and Company | $144.18 | 2025 | Maxplus |
| Qiagen, LLC | $130.80 | 2019 | |
| Comsort, INC | $100.00 | 2019 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Melinta Therapeutics, LLC | $68.06 | 2019-2023 | Orbactiv, Kimyrsa, Rezzayo |
| Aimmune Therapeutics, INC. | $62.52 | 2025 | Vowst |
| La Jolla Pharmaceutical Company | $47.88 | 2021-2023 | Xerava |
| Dynavax Technologies Corporation | $40.83 | 2019-2023 | Heplisav-B |
| Janssen Scientific Affairs, LLC | $30.10 | 2020 | |
| Nabriva Therapeutics, Plc | $29.36 | 2021 | |
| Electromed, INC. | $28.94 | 2021-2022 | |
| Philips North America LLC | $23.54 | 2024 | (Ak6) Vest Therapy |
| Sanofi Pasteur INC. | $21.64 | 2022 | |
| Theratechnologies INC. | $13.40 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Sidebottom listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.